| 摘要 |
The invention describes a pharmaceutical product for the treatment of viral infections, in particular of the human immunodeficiency virus (HIV). According to the invention, the pharmaceutical product comprises a compound that as active component contains an iron chelator. Suitable iron chelators are selected from the group of hydroxamates (such as deferoxamine), the family of the hydroxypyridinons (such as deferiprone), and the nucleic acid-binding chemotherapeutical products (such as bleomycine). A synergistic effect is obtained in vitro when in addition to the component containing the iron chelator, a product is used that contains another virus-inhibiting compound. As the antiviral agent a protease-inhibitor, preferably ritonavir, is considered. Another suitable antiviral agent is a reverse transcriptase inhibitor, preferably a dideoxyinosine. |
